A study of WVE-210201 (dystrophin exon 51) for the treatment of Duchenne muscular dystrophy (DMD)

Trial Profile

A study of WVE-210201 (dystrophin exon 51) for the treatment of Duchenne muscular dystrophy (DMD)

Planning
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs WVE 210201 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Sep 2016 New trial record
    • 15 Aug 2016 According to a WaVe life Sciences media release, the company is planning to file an Investigational New Drug Application (IND) in 2017 and anticipates to initiate clinical trial in second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top